Alamar Biosciences Management
Management criteria checks 3/4
Alamar Biosciences' CEO is Yuling Luo, appointed in May 2018, has a tenure of 8.33 years. total yearly compensation is $3.28M, comprised of 14.8% salary and 85.2% bonuses, including company stock and options. directly owns 4.45% of the company’s shares, worth $107.62M. The average tenure of the management team and the board of directors is 3.1 years and 3.5 years respectively.
Key information
Yuling Luo
Chief executive officer
US$3.3m
Total compensation
| CEO salary percentage | 14.76% |
| CEO tenure | 8.3yrs |
| CEO ownership | 4.5% |
| Management average tenure | 3.1yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
ALMR: Expanded Neuro Partnerships And Immune Panel Will Support Steady Future Progress
Analysts have modestly raised their price target for Alamar Biosciences from $31.80 to $33.40. This change reflects updated assumptions on the discount rate, revenue growth, profit margin, and future P/E expectations.Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument
Summary Alamar Biosciences is building a content-driven proteomics platform, with accelerating consumables revenue and expanding biomarker panels driving long-term growth. Q2 2026 revenue grew 82% YoY to $29.4M, with consumables sales up 147% and gross margin rising to 60%, highlighting improving revenue quality and operational leverage potential. ALMR's installed base enables capital-efficient expansion, with new assays deployable across existing instruments, creating workflow stickiness and recurring revenue opportunities. I remain bullish, despite premium valuation and execution risks, as consumables growth, margin expansion, and large-scale neuro collaborations underpin a compelling long-term thesis. Read the full article on Seeking AlphaBlood Biomarker Demand And New Panels Will Support Long-Term Neurology And Immunology Upside
Catalysts About Alamar Biosciences Alamar Biosciences develops ultra high sensitivity multiplex proteomics platforms used in disease research and potential future diagnostic applications. What are the underlying business or industry changes driving this perspective?CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$50m |
| Mar 31 2026 | n/a | n/a | -US$43m |
| Dec 31 2025 | US$3m | US$483k | -US$30m |
Compensation vs Market: Yuling's total compensation ($USD3.28M) is below average for companies of similar size in the US market ($USD7.02M).
Compensation vs Earnings: Insufficient data to compare Yuling's compensation with company performance.
CEO
Yuling Luo (62 yo)
Dr. Yuling Luo, Ph D., is a Venture Partner at Iif Management Company, LLC. He served as Co-Founder and Director of Attovia Therapeutics, Inc. From August 2016 to February 2018 until July 15, 2026, Dr. Luo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.3yrs | US$3.28m | 4.45% $ 107.6m | |
| Co-Founder | 8.1yrs | US$1.58m | 1.04% $ 25.2m | |
| Chief Financial Officer | less than a year | US$1.94m | no data | |
| President | less than a year | no data | 0.66% $ 15.8m | |
| Co-Founder | no data | no data | no data | |
| Chief Technology Officer | 5.3yrs | no data | no data | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior Vice President of Sales | no data | no data | no data | |
| Senior Vice President of Marketing | no data | no data | no data | |
| Senior VP of AI & Strategic Initiatives | no data | no data | no data |
Experienced Management: ALMR's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.3yrs | US$3.28m | 4.45% $ 107.6m | |
| Co-Founder | 6.3yrs | US$1.58m | 1.04% $ 25.2m | |
| Independent Director | 6.3yrs | no data | no data | |
| Lead Independent Director | less than a year | no data | 0% $ 0 | |
| Director | no data | no data | no data | |
| Independent Director | less than a year | no data | no data |
Experienced Board: ALMR's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 20:53 |
| End of Day Share Price | 2026/09/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alamar Biosciences, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ryskin | BofA Global Research |
| Avantika Dhabaria | BofA Global Research |
| Casey Woodring | J.P. Morgan |